Skip to content

Characterisation of availability in the body of the active substance(s) of the newly developed patch Esflurbiprofen Topical System (EFTS) in comparison with a marketed oral flurbiprofen-containing tablet formulation after multiple dose administration including adhesion assessment of the patch - a phase I, open-label, randomised, 2-period, cross-over study in healthy subjects

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-513058-31-00
Acronym
TK-254RX-0102
Enrollment
26
Registered
2024-10-09
Start date
2025-01-07
Completion date
2025-02-24
Last updated
2024-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bioavailability and patch adhesion trial with healthy volunteers, therapeutic indication not studied

Interventions

None listed

Sponsors

Teikoku Seiyaku Co. Ltd.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026